Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Fosaprepitant dimeglumine - Generic Drug Details

« Back to Dashboard

What are the generic sources for fosaprepitant dimeglumine and what is the scope of patent protection?

Fosaprepitant dimeglumine
is the generic ingredient in two branded drugs marketed by Merck And Co Inc and Fresenius Kabi Usa, and is included in two NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fosaprepitant dimeglumine has thirty-six patent family members in twenty-seven countries.

There are eight drug master file entries for fosaprepitant dimeglumine. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: fosaprepitant dimeglumine

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list8
Suppliers / Packagers: see list1
Bulk Api Vendors: see list58
Clinical Trials: see list17
Patent Applications: see list166
Drug Prices:see low prices
DailyMed Link:fosaprepitant dimeglumine at DailyMed

Tentative approvals for FOSAPREPITANT DIMEGLUMINE

Applicant Application No. Form Dosage
► Subscribe► SubscribeINJECTABLE;INJECTION150MG
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNYesNo5,691,336► SubscribeYY ► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010APRXYesYes5,691,336► SubscribeYY ► Subscribe
Fresenius Kabi Usa
FOSAPREPITANT DIMEGLUMINE
fosaprepitant dimeglumine
POWDER;INTRAVENOUS206197-001Jun 9, 2016APRXNoNo► Subscribe► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot